# Oman Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Oman HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Oman (OMN)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $375.6M
- Products: 27
- Buyer markets: 27
- Average CAGR: +58.9%
- Global sector size: $503.3B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $309.2B | $22.0M | $116.3B | +27.6% | 22 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $26.1B | $115.3 | $21.8B | -24.2% | 6 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $24.5B | $946.8K | $14.7B | +393.1% | 7 | +0.0% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $27.4B | $1.0K | $9.6B | +210.7% | 3 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $18.2B | $17.4K | $8.0B | +7.3% | 4 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $16.0B | $73.9 | $7.8B | -10.6% | 2 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $8.0B | $44.6K | $6.2B | +28.9% | 2 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $9.4B | $1.9M | $6.2B | +20.4% | 4 | +0.0% |
| HS 290243 - Cyclic hydrocarbons: p-xylene | $8.5B | $63.2M | $6.2B | -2.6% | 1 | +0.7% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $6.7B | $40.7K | $5.5B | +5.7% | 2 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $12.4B | $3.4K | $4.6B | -7.7% | 3 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $5.5M | $4.1B | +15.7% | 2 | +0.1% |
| HS 290220 - Cyclic hydrocarbons: benzene | $4.1B | $31.6M | $3.4B | +6.2% | 1 | +0.8% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $2.0B | $37.3K | $2.9B | +12.5% | 2 | +0.0% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $2.8B | $38.8 | $2.6B | -5.1% | 2 | +0.0% |
| HS 290121 - Acyclic hydrocarbons: unsaturated, ethylene | $1.8B | $83.8M | $2.2B | +131.4% | 1 | +4.6% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $71.6 | $2.1B | +84.4% | 1 | +0.0% |
| HS 290531 - Alcohols: acyclic, diols: ethylene glycol (ethanediol) | $3.2B | $153.9M | $2.0B | +42.2% | 1 | +4.8% |
| HS 291736 - Acids: aromatic polycarboxylic acids: terephthalic acid and its salts | $1.6B | $1.7K | $1.4B | -32.1% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $3.0 | $1.4B | -54.5% | 1 | +0.0% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $2.0B | $12.7M | $1.3B | +45.0% | 1 | +0.6% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $1.1B | $21.8K | $1.1B | +166.4% | 1 | +0.0% |
| HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $19.4 | $1.1B | -16.8% | 1 | +0.0% |
| HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $2.7B | $0.1 | $1.0B | -66.8% | 1 | +0.0% |
| HS 320611 - Colouring matter: pigments and preparations based on titanium dioxide, containing 80% or more by weight of titanium dioxide calculated on the dry matter | $1.1B | $1.1K | $997.2M | +3.9% | 1 | +0.0% |
| HS 294190 - Antibiotics: n.e.c. in heading no. 2941 | $883.6M | $40.2K | $990.0M | -3.0% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $2.0B | $226.7 | $981.0M | +82.8% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $44.2B calculated opportunity across 9 products.
- Switzerland, Liechtenstein (CHE): $30.7B calculated opportunity across 2 products.
- China (CHN): $26.6B calculated opportunity across 8 products.
- Germany (DEU): $23.1B calculated opportunity across 9 products.
- Belgium (BEL): $18.4B calculated opportunity across 3 products.
- Netherlands (NLD): $15.4B calculated opportunity across 5 products.
- United Kingdom (GBR): $12.3B calculated opportunity across 6 products.
- Slovenia (SVN): $9.7B calculated opportunity across 1 products.
- France (FRA): $7.8B calculated opportunity across 5 products.
- Spain (ESP): $6.6B calculated opportunity across 2 products.
- Canada (CAN): $6.3B calculated opportunity across 3 products.
- Italy (ITA): $4.9B calculated opportunity across 1 products.

## Growth stars

- HS 382499: +393.1% average CAGR, $14.7B calculated opportunity.
- HS 300215: +210.7% average CAGR, $9.6B calculated opportunity.
- HS 330210: +166.4% average CAGR, $1.1B calculated opportunity.
- HS 290121: +131.4% average CAGR, $2.2B calculated opportunity.
- HS 381512: +84.4% average CAGR, $2.1B calculated opportunity.
- HS 300390: +82.8% average CAGR, $981.0M calculated opportunity.
- HS 290919: +45.0% average CAGR, $1.3B calculated opportunity.
- HS 290531: +42.2% average CAGR, $2.0B calculated opportunity.
- HS 382600: +28.9% average CAGR, $6.2B calculated opportunity.
- HS 300490: +27.6% average CAGR, $116.3B calculated opportunity.

## Diversification opportunities

- HS 300490: 22 buyer markets, $116.3B calculated opportunity.
- HS 382499: 7 buyer markets, $14.7B calculated opportunity.
- HS 300220: 6 buyer markets, $21.8B calculated opportunity.
- HS 330499: 4 buyer markets, $8.0B calculated opportunity.
- HS 300439: 4 buyer markets, $6.2B calculated opportunity.
- HS 300215: 3 buyer markets, $9.6B calculated opportunity.
- HS 382200: 3 buyer markets, $4.6B calculated opportunity.
- HS 300212: 2 buyer markets, $7.8B calculated opportunity.
- HS 382600: 2 buyer markets, $6.2B calculated opportunity.
- HS 293499: 2 buyer markets, $5.5B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.